Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


X-SCID Gene Therapy Risks Not Generalizable To Other Conditions, Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Cellular, Tissue & Gene Therapies Advisory Committee points to unique factors in the biological basis of X-linked severe combined immunodeficiency disorder and the fact that leukemia cases have been seen in only one study.

You may also be interested in...

FTC Suffers Reversal On “Reverse Payments” Enforcement

The Solicitor General says the Supreme Court should not hear the Commission's appeal of a case brought against Schering-Plough regarding a generic drug settlement.

AstraZeneca Collaborations Moving From “Deals” To “Relationships”

Fox Chase Cancer Center’s Weeks concurs that umbrella agreements with pharma and biotech companies are becoming more common.

Pharmacogenetic Dosing Recommendations Sorely Needed By Clinicians, Formularies, SACGHS Says

Tests are currently available to identify patient responders, but clinicians need guidance on how to adjust dosing for them, the HHS Secretary's Advisory Committee on Genetics, Health & Society agreed.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts